User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

6377

Interactions with Platform & by Email *

INTERACTIONS

1020

Unique # Participated *

PARTICIPANTS

191

Responses Validated *

VALIDATIONS

41

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Introduction.....II-1
Bladder Cancer Growing at an Alarming Rate.....II-1
Bladder Cancer Statistics.....II-1
Table 1: Worldwide Incidence of Bladder Cancer by Select Countries/Region (2003 & 2013): US, Europe, and Japan (In '000s) (includes corresponding Graph/Chart).....II-1
1$300
   Table 2: Worldwide Incidence and Mortality Rates of Select Cancer Types in Males: 2007 (includes corresponding Graph/Chart).....II-21$300
   Table 3: Incidence and Mortality Rates of Select Cancer Types in Developed Markets: 2007 (includes corresponding Graph/Chart).....II-31$300
   Table 4: Incidence and Mortality Rates of Select Cancer Types in Developing Markets: 2007 (includes corresponding Graph/Chart).....II-4
Recurrent Nature: A Major Cause of Concern.....II-4
1$300
   Bladder Cancer: The Most Costly Cancer To Treat.....II-5
Generics Characterize Bladder Cancer Market.....II-5
Existing Drug Therapies Lack in Assuring Long Term Survival Rate.....II-5
1$100
   Approved Intravesical Agents for Bladder Cancer.....II-6
Bladder Cancer Demands New Therapeutics to Fill the Void.....II-6
1$100
   Table 5: Number of Pipeline Drugs by Select Cancer Types (includes corresponding Graph/Chart).....II-7
What the Future Holds?.....II-7
Table 6: World Market for Bladder Cancer Therapeutics (2008): Percentage Share Breakdown of Total Number of Drugs by Development Stage (includes corresponding Graph/Chart).....II-7
1$300
   Emerging Therapeutic Options for Superficial Bladder Cancer.....II-8
Table 7: EOquin Penetration Rate in the US for the Years 2011 through 2015 (includes corresponding Graph/Chart).....II-8
1$300
   Table 8: US Market for EOquin: Annual Revenue Projections for the Years 2011 through 2015 in US$ Million (includes corresponding Graph/Chart).....II-9
Registration Process for New Drugs: A Review.....II-9
Competitive Landscape.....II-9
1$300
   Leading Therapeutics in Global Bladder Cancer Market.....II-10
Select Companies Involved in Late-Stage Bladder Cancer Clinical Trials.....II-10
1$100
   Select Companies Involved in Phase-II Clinical Trials.....II-11
Select Companies Involved in Phase-I Clinical Trials.....II-11
Select Companies Involved in Pre-clinical Stage.....II-11
Current and Future Analysis.....II-11
2$125
   Cigarette Smoking and Carcinogenic Substances: The Major Culprits.....II-13
Men at High Risk than Women.....II-13
New Therapeutics for Elderly Population: Need of the Hour.....II-13
Lasers for Bladder Cancer Treatment: An Evolving Approach.....II-13
1$100
   Photodynamic Therapy (PDT) Holds Potential.....II-14
SonoPhoto Dynamic Therapy – A New Treatment for Non-Invasive Bladder Cancer.....II-14
1$100
   Non-Invasive (Superficial) Bladder Cancer Treatment.....II-15
Treatment Options and Potential Side Effects.....II-15
Surgery.....II-15
1$100
   Immunotherapy.....II-16
Intravesical Chemotherapy.....II-16
1$100
   Invasive Bladder Cancer Treatment.....II-17
Treatment Options, and Potential Side Effects.....II-17
Surgery.....II-17
Cystectomy.....II-17
Partial Cystectomy – A Part of Bladder is Removed.....II-17
Radical Cystectomy – Entire Bladder is Removed.....II-17
1$100
   Side Effects of Removing the Bladder.....II-18
What’s the Solution if the Bladder Is Removed?.....II-18
Reconstructive Surgery.....II-18
Continent Urinary Diversion or Ileal Loop Diversion.....II-18
Neobladder.....II-18
1$100
   Radiotherapy.....II-19
Systemic Chemotherapy.....II-19
1$100
   Metastatic Bladder Cancer.....II-20
Palliative Treatment.....II-20
Other Treatment Options.....II-20
Targeted Therapy.....II-20
Gene Therapy.....II-20
Chemoprevention.....II-20
1$100
   Chemoradiotherapy.....II-21
Photodynamic Therapy (PDT).....II-21
Complementary Therapies.....II-21
1$100
   A Quick Market Primer.....II-22
Leading Bladder Cancer Therapeutics.....II-22
1$100
   Select Bladder Cancer Therapeutics in Pipeline: 2009.....II-231$100
   Approved Bladder Cancer Drugs.....II-24
Thiotepa.....II-24
Adriamycin (Doxorubican hydrochloride).....II-24
Methotrexate.....II-24
Vinblastine.....II-24
Epirubicin.....II-24
Mitomycin C.....II-24
1$100
   Mitoxzantrone.....II-25
Oxaliplatin.....II-25
IL2 (Aldesleukin) and Interferon into the Bladder.....II-25
Keyhole Limpet Haemocyanin (KLH).....II-25
Platinol-AQ (Cisplatin).....II-25
1$100
   Gemzar (Gemcitabine).....II-26
OncoTICE/TICE BCG.....II-26
PACIS™ BCG.....II-26
Valstar (valrubicin).....II-26
1$100
   Late-Stage Pipeline Drugs.....II-27
EOquin (Apaziquone).....II-27
Urocidin (MCC).....II-27
1$100
   Larotaxel (XRP-9881).....II-28
Javlor® (Vinflunine).....II-28
4-HPR (Fenretinide).....II-28
Pipeline Analysis of Other Potential Drugs.....II-28
BEXIDEM [On-Hold].....II-28
1$100
   BC-819 [Phase IIb].....II-29
CDX-1307 [Phase I].....II-29
Chemophase® [Phase I/IIa].....II-29
1$100
   PDX [Pralatrexate] [Phase II].....II-30
OGX-427 [Phase I].....II-30
OGX-011 [Phase II].....II-30
Celebrex (Celecoxib) [Phase IIb/III].....II-30
TMX-101 [Pre-Clinical Stage].....II-30
1$100
   AGSPSCA [Phase Ib].....II-31
Iressa with Gemzar [Phase II].....II-31
MDR09521[Development Stage].....II-31
siRNA ALPHAGEN [Development Stage].....II-31
1$100
   Cancer – An Insight.....II-32
Factors Causing Cancer Ranked in Order of Impact.....II-32
1$100
   Cancer Diagnosis.....II-33
Treatment Strategies for Cancer.....II-33
Progressing R&D Efforts to Innovate Drug Delivery for Cancer Treatment.....II-33
The Human Bladder: A Urine Storing Organ.....II-33
1$100
   Bladder Cancer – Introduction.....II-34
Classification of Bladder Cancer.....II-34
Non-Invasive Cancer.....II-34
Invasive Cancer.....II-34
1$100
   Types of Bladder Cancer.....II-35
Transitional Cell Carcinoma/Urothelial Carcinoma.....II-35
Squamous Cell Carcinoma.....II-35
Adenocarcinoma.....II-35
Table 9: US Prevalence of Bladder Cancer by Type (includes corresponding Graph/Chart).....II-35
1$300
   Major Risk Factors.....II-36
Controllable Risk Factors.....II-36
Uncontrollable Risk Factors.....II-36
1$100
   Symptoms and Diagnosis.....II-37
Symptoms.....II-37
Diagnosis.....II-37
General Diagnostic Tests.....II-37
Blood Tests.....II-37
1$100
   Physical Examination.....II-38
Urine Test.....II-38
Prescribed Procedure to Locate Bladder Cancer.....II-38
Cytoscopy and Biopsy.....II-38
Intravenous Pyelogram (IVP).....II-38
Ultrasound Scanning.....II-38
Test/Procedures to Confirm Cancer Penetration.....II-38
CT Scan.....II-38
1$100
   Radioisotope Bone Scan.....II-39
Staging and Grading of Bladder Cancer: Crucial for Treatment.....II-39
Staging.....II-39
Grading.....II-39
2$125
   Variations in PSCA Gene Increase Risk of Bladder Cancer.....II-41
Genetic Analysis for Assaying Bladder Cancer Recurrence.....II-41
Selenium Allays the Risk of Bladder Cancer.....II-41
1$100
   Individuals with Common Genome Variants at Increased Risk of Developing Bladder
  Cancer.....II-42
New Studies Reveal Correlation Between Coffee and Bladder Cancer.....II-42
Raw Cruciferous Vegetables Alleviates the Risk of Bladder Cancer.....II-42
1$100
   Broccoli Sprouts a Super-Food to Prevent Bladder Cancer.....II-43
Well Water Counts to the Risk Factors for the Bladder cancer.....II-43
Frankincense Oil: Potentially a Future Aid for Bladder Cancer.....II-43
1$100
   SRC Gene Suppresses Bladder Cancer Metastases.....II-441$100
   Allos Therapeutics Obtains FDA Orphan Drug Designation for Pralatrexate.....II-45
Aeterna Zentaris Secures FDA Approval for IND Application of AEZS-108.....II-45
Biocancell Obtains FDA Clearance to Continue Clinical Trial for BC-819.....II-45
Bioniche to Commence Additional Phase III Clinical Trial of Urocidin™.....II-45
1$100
   Bioniche Obtains FDA Approval for Phase III Trial of Urocidin.....II-46
FDA Grants Fast Track Designation for Apaziquone (EOquin®).....II-46
1$100
   Indevus Receives FDA Nod for Valstar.....II-47
Biocancell Obtains FDA Approval of BC-819 for Phase IIb Clinical Trail.....II-47
1$100
   MDRNA Takes Over Cequent Pharmaceuticals.....II-48
MDRNA Changes Name to Marina Biotech.....II-48
Telormedix Commences Phase I/II clinical Trial for TMX-101.....II-48
1$100
   Spectrum and Handok Ink Joint Marketing Agreement for Apaziquone in Korea.....II-49
MDRNA Expands and Extends Collaboration with VPC.....II-49
Endo Pharmaceuticals Acquires Indevus Pharmaceuticals.....II-49
Affitech Merges with Pharmexa.....II-49
1$100
   Takeda America Holdings Acquires IDM Pharma.....II-50
Schering-Plough Merges with Merck.....II-50
Cell Genesys Merges with BioSante Pharmaceuticals.....II-50
Celldex Therapeutics Acquires CuraGen.....II-50
1$100
   EMEA Grants Orphan Medicinal Product Designation for Pralatrexate.....II-51
Endo Pharmaceuticals Obtains License for Urocidin.....II-51
CHMP Issues Positive Opinion on JAVLOR® to Treat Metastatic Bladder Cancer.....II-51
BioCis Pharma Initiates Phase I Clinical Trial of ProtoCure™.....II-51
1$100
   Sonus Pharmaceuticals Acquires OncoGenex Technologies.....II-52
Callisto Merges with Celldex Therapeutics.....II-52
Allergan and Spectrum Pharmaceuticals Collaborate for Apaziquone.....II-52
1$100
   Pro-Pharmaceuticals and BioCancell Collaborate to Administer siRNA for H19 Genes
  Destruction in Cancerous Cells.....II-53
AVANT Adopts New Identity as Celldex Therapeutics.....II-53
Lorus Therapeutics Receives New Patent for LOR-2040, Leukemia Drug.....II-53
1$100
   Spectrum Pharmaceuticals Obtains Canadian Authorities Approval for Phase III Clinical
  Trial of EOquin.....II-54
NCCN Obtains Grant to Evaluate Cetuximab Efficacy in Bladder Cancer.....II-54
Allos Therapeutics Commences Phase II Trials for Pralatrexate.....II-54
Halozyme Announces Status Update of Chemophase® Phase I/IIa Clinical Trial.....II-54
1$100
   Spectrum Pharmaceuticals Establishes New Company in Canada.....II-55
China Medical Technologies Acquires FISH Business.....II-55
Peregrine Acquires Global License for Anti-Angiogenesis Technology.....II-55
1$100
   Bristol-Myers Terminates Partnership with Pierre Fabre.....II-561$100
   Affitech A/S (Denmark).....II-57
Allergan, Inc. (USA).....II-57
1$100
   Allos Therapeutics, Inc. (USA).....II-58
Astellas Pharma, Inc. (Japan).....II-58
Astrazeneca Plc. (UK).....II-58
AVI BioPharma, Inc. (USA).....II-58
1$100
   BioCancell Therapeutics, Inc. (Israel).....II-59
Bioniche Life Sciences, Inc. (Canada).....II-59
1$100
   Bristol-Myers Squibb Company (USA).....II-60
Celldex Therapeutics, Inc. (USA).....II-60
1$100
   Cytavis BioPharma GmbH (Germany).....II-61
Eli Lilly and Company (USA).....II-61
1$100
   Endo Pharmaceuticals Holdings, Inc. (USA).....II-62
ENKAM Pharmaceuticals A/S (Denmark).....II-62
F. Hoffmann-La Roche Ltd. (Switzerland).....II-62
1$100
   Halozyme Therapeutics, Inc. (USA).....II-63
Laboratoires Pierre Fabre SA (France).....II-63
NatImmune A/S (Denmark).....II-63
1$100
   Oncogenex Pharmaceuticals, Inc. (USA).....II-64
OncoTherapy Science, Inc. (Japan).....II-64
Sanofi-Aventis (France).....II-64
1$100
   Spectrum Pharmaceuticals, Inc. (USA).....II-65
Telormedix SA (Switzerland).....II-65
1$100
   Viventia Biotechnologies, Inc. (Canada).....II-661$100
   Table 10: World Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart).....II-671$300
   Table 11: World Historic Review for Bladder Cancer Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart).....II-681$300
   Table 12: World 11-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Revenues for US, Japan, Europe, and Rest of World Markets for the Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-691$300
   A. Market Analysis.....III-1
Bladder Cancer & Prevalence – A Recapitulation of Facts.....III-1
1$75
   Mortality Rates Higher in African Americans.....III-2
Table 13: Incidence of Bladder Cancer Among African American (Males): Percentage Share Breakdown by Select Cancer/Type or Site for the Year 2007 (includes corresponding Graph/Chart).....III-2
Bladder Cancer - A Costly Urologic Condition.....III-2
1$150
   Table 14: Urologic Disease Costs in the US: 2006 (includes corresponding Graph/Chart).....III-3
US Bladder Cancer Statistics.....III-3
Table 15: Bladder Cancer Prevalence and Mortality in the US by Gender: Percentage Share Breakdown for 2009 (includes corresponding Graph/Chart).....III-3
1$150
   Table 16: Bladder Cancer Incidence in the US by Gender: Percentage Share Breakdown for 2008 (includes corresponding Graph/Chart).....III-4
FDA Approval.....III-4
2$150
   Strategic Corporate Developments.....III-66$175
   Select Players.....III-12
Allergan, Inc......III-12
Allos Therapeutics, Inc......III-12
1$75
   AVI BioPharma, Inc......III-13
Bristol-Myers Squibb Company.....III-13
1$75
   Celldex Therapeutics, Inc......III-14
Eli Lilly and Company.....III-14
1$75
   Endo Pharmaceuticals Holdings, Inc......III-15
Halozyme Therapeutics, Inc......III-15
Marina Biotech, Inc......III-15
1$75
   Oncogenex Pharmaceuticals, Inc......III-16
Peplin, Inc......III-16
Polyphenon Pharma.....III-16
1$75
   Spectrum Pharmaceuticals, Inc......III-171$75
   B. Market Analytics.....III-18
Table 17: US Recent Past, Current and Future Analysis for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart).....III-18
1$150
   Table 18: US Historic Review for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart).....III-191$150
   A. Market Analysis.....III-20
Current & Future Analysis.....III-20
Select Players.....III-20
alphaGEN, Co., Ltd.....III-20
Astellas Pharma, Inc......III-20
Nippon Kayaku Co., Ltd.....III-20
1$75
   OncoTherapy Science, Inc......III-211$75
   B. Market Analytics.....III-22
Table 19: Japanese Recent Past, Current and Future Analysis for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart).....III-22
1$150
   Table 20: Japanese Historic Review for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart).....III-231$150
   A. Market Analysis.....III-24
Current & Future Analysis.....III-24
Bladder Cancer – Prevalence.....III-24
Table 21: Bladder Cancer Incidence in Europe by Region (2006) for Germany, Italy, Spain, France, The UK, Scandinavia, and Benelux (includes corresponding Graph/Chart).....III-24
1$150
   Table 22: Bladder Cancer Mortality in Europe by Region (2006) for Germany, Italy, the UK, Spain, France, Benelux, and Scandinavia (includes corresponding Graph/Chart).....III-25
Europe Lacks R&D Innovation in Bladder Cancer Market.....III-25
Focus on Select Regional Market.....III-25
United Kingdom.....III-25
Bladder Cancer Prevalence – A Review.....III-25
1$150
   Bladder Cancer Statistics in the UK.....III-26
Table 23: Incidence, Mortality, and Five-Year Survival Rate of Bladder Cancer in UK by Gender: 2006.....III-26

Table 24: Bladder Cancer Incidence by Region (2006) for England, Wales, Scotland, and Northern Ireland (includes corresponding Graph/Chart).....III-26
1$150
   Table 25: Age-Specific Incidence of Bladder Cancer by Gender: 2006 (includes corresponding Graph/Chart).....III-27

Table 26: Number of Bladder Cancer Deaths in the UK (2007): Breakdown by Region - England, Wales, Scotland, and Northern Ireland (includes corresponding Graph/Chart).....III-27

Table 27: Age-Specific Bladder Cancer Mortality Rate in UK Males: Breakdown by Age Group for 2007 (includes corresponding Graph/Chart).....III-27
1$150
   Table 28: Age-Specific Bladder Cancer Mortality Rate in UK Females: Breakdown by Age Group for 2007 (includes corresponding Graph/Chart).....III-28
Strategic Corporate Developments.....III-28
1$150
   Select Players.....III-29
Affitech A/S (Denmark).....III-29
1$75
   Astrazeneca PLC (UK).....III-30
BioCis Pharma Ltd (Finland).....III-30
Cambridge Laboratories Ltd. (UK).....III-30
curasan AG (Germany).....III-30
1$75
   Cytavis BioPharma GmbH (Germany).....III-31
ENKAM Pharmaceuticals A/S (Denmark).....III-31
F. Hoffmann-La Roche Ltd. (Switzerland).....III-31
1$75
   Laboratoires Pierre Fabre SA (France).....III-32
NatImmune A/S (Denmark).....III-32
Sanofi-Aventis (France).....III-32
1$75
   Telormedix SA (Switzerland).....III-331$75
   B. Market Analytics.....III-34
Table 29: European Recent Past, Current and Future Analysis for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart).....III-34
1$150
   Table 30: European Historic Review for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart).....III-351$150
   A. Market Analysis.....III-36
Current & Future Analysis.....III-36
Select Markets.....III-36
Canada.....III-36
Bladder Cancer Treatment.....III-36
Bladder Cancer Statistics.....III-36
Table 31: Bladder Cancer New Cases in Canada: Percentage Share Breakdown by Gender for 2009 (includes corresponding Graph/Chart).....III-36
1$150
   Table 32: Bladder Cancer Mortality in Canada: Percentage Share Breakdown by Gender for 2009 (includes corresponding Graph/Chart).....III-37

Table 33: New Cases of Cancer Among Canadian Females by Cancer Type: Percentage Share Breakdown for 2009 (includes corresponding Graph/Chart).....III-37
1$150
   Table 34: Cancer Mortality Among Canadian Females by Cancer Type: Percentage Share Breakdown for 2009 (includes corresponding Graph/Chart).....III-38

Table 35: New Cases of Cancer Among Canadian Males by Cancer Type: Percentage Share Breakdown for 2009 (includes corresponding Graph/Chart).....III-38
1$150
   Table 36: Cancer Mortality among Canadian Males by Cancer Type: Percentage Share Breakdown for 2009 (includes corresponding Graph/Chart).....III-39
Asia-Pacific.....III-39
China.....III-39
India.....III-39
1$150
   Australia.....III-40
Women at Increased Risk Over Men in Australia – A New Finding.....III-40
Table 37: Number of Deaths Due to Bladder Cancer: Breakdown by Age Group for the Year 2006 (includes corresponding Graph/Chart).....III-40
1$150
   Table 38: Age-Standardized Mortality Rate Due to Bladder Cancer in Australia: Breakdown by Age Group for the Year 2006 (includes corresponding Graph/Chart).....III-41

Table 39: Number of Deaths Due to Bladder Cancer (Males): Breakdown by Age Group for the Year 2006 (includes corresponding Graph/Chart).....III-41
1$150
   Table 40: Number of Deaths Due to Bladder Cancer (Females): Breakdown by Age Group for the Year 2006 (includes corresponding Graph/Chart).....III-42
South Africa – Prevalence.....III-42
FDA Approval.....III-42
1$150
   Strategic Corporate Developments.....III-431$75
   Select Players.....III-44
BioCancell Therapeutics, Inc. (Israel).....III-44
Bioniche Life Sciences, Inc. (Canada).....III-44
1$75
   China Medical Technologies Inc. (China).....III-45
Lorus Therapeutics, Inc. (Canada).....III-45
PharmaGap, Inc. (Canada).....III-45
1$75
   Viventia Biotechnologies, Inc. (Canada).....III-461$75
   B. Market Analytics.....III-47
Table 41: Rest of World Recent Past, Current and Future Analysis for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart).....III-47
1$150
   Table 42: Rest of World Historic Review for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart).....III-481$150
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com